I know that many are wondering what might be if TT-034 proves to...

I know that many are wondering what might be if TT-034 proves to be efficacious and validates ddRNAi so I thought that I would post a good news story to keep the imagination stirred.

Juno is a biotech with a primary interest in CAR T technology. They have a number of Pl and Pl/ll trials on the go for blood cancers. At the beginning of June this year, they announced promising results from one of their Pl trials. Four weeks later, they announced a deal with Celgene in which Celgene paid them $1B upfront. Juno's mc is now $4.7B. When it IPO'ed in December last year it had a mc circa $2.8B.

Let's hope that good results will deliver even greater degrees of magnitude of success for Benitec as we are starting from a much lower base.